Moderna Surges Over 170% on Melanoma Vaccine, Ushering in a Golden Era for mRNA?

Moderna's personalized mRNA tumor vaccine, intismeran autogene (mRNA-4157/V940), developed in collaboration with Merck, met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase III trial (INTerpath-001) as an adjuvant therapy for high-risk melanoma in combination with Keytruda—marking the first successful Phase III result for an mRNA tumor vaccine globally.